https://www.selleckchem.com/pr....oducts/pf-05221304.h
Immunotherapy with checkpoint inhibitor programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) antibodies targeting the cellular immune checkpoints is the present area of interest showing promising results in patients with advanced non-small cell lung cancer (NSCLC). As there is paucity of PD-L1 expression data from the Indian perspective, we studied the correlation of clinicopathologic profile and oncogenic driver mutations in these patients. Samples from 252 advanced NSCLCs patients were studied for PD-L1 expression throu
Beğen
Yorum Yap
Paylaş
